Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Kymera Therapeutics Q3 EPS $(0.94) Misses $(0.83) Estimate, Sales $2.764M Miss $18.852M Estimate

Author: Benzinga Newsdesk | November 04, 2025 07:02am
Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.94) per share which missed the analyst consensus estimate of $(0.83) by 13.12 percent. This is a 14.63 percent decrease over losses of $(0.82) per share from the same period last year. The company reported quarterly sales of $2.764 million which missed the analyst consensus estimate of $18.852 million by 85.34 percent. This is a 26.12 percent decrease over sales of $3.741 million the same period last year.

Posted In: KYMR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist